. 2019 Nov 6;20(22):5525. doi: 10.3390/ijms20225525

Table 3.

Patient characteristics and outcomes of clinical trials with romosozumab. PMO: postmenopausal osteoporosis, M with OP: men with osteoporosis, romo.: romosozumab, deno.: denosumab, TPTD: teriparatide, ALN: alendronate, M: every month(s), W: every week, D: every day, BMD: bone mineral density.

Study	Patient	Group	Participants	Age	Protocol	Length	BMD (%)		New Fracture (%)	Bone Turnover Marker (Maximum %)
[Ref No.]	Patient	Group	(N)	(Year)	Protocol	Length	Lumber Spine	Total Hip	New Fracture (%)	P1NP	CTX
FRAME [125,126]	PMO	All	7180	70.8		12months			after 24 months	on day 14
		Treatment	3589	70.9	210mg romo./1M ⇒60mg deno./6M	⇩	+17.6	+8.8	0.6	+150	−50
		Control	3591	70.8	placebo/1M ⇒60mg deno./6M	12months	+5.0	+2.9	2.5	no change	no change
STRUCTURE [125,127]	PMO	All	436	71.5		12months			no data	on day 14
		Treatment	218	71.8	210mg romo./1M		+9.8	+2.9		+180	+30
		Control	218	71.2	20μg TPTD/1D		+5.4	−0.5		+30	no change
ARCH [125,128]	PMO	All	4093	74.3		12months			after 24 months	on 1 month
		Treatment	2046	74.4	210mg romo./1M ⇒70mg ALN./1W	⇩	+14.9	+8.5	6.2	+80	−40
		Control	2047	74.2	70mg ALN./1W ⇒70mg ALN./1W	24months	+7.0	+3.6	11.9	−10	−60
BRIDGE [129]	M with OP	All	245	72.1					no data	on 1 month
		Treatment	163	72.4	210mg romo./1M	12months	+12.1	+2.5		+85.8	−30.8
		Control	82	71.5	placebo/1M		+1.2	−0.5		+1.2	−1.7